99 filings
Page 2 of 5
8-K
vt7jhw cft06t7j
3 Aug 22
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
6:46am
8-K
n3dod
13 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
3kd7nmtr7x6v
4 May 22
Editas Medicine Announces First Quarter 2022 Results and Business Updates
7:00am
8-K
vncg6hwq k24fzl82s5o
14 Apr 22
Departure of Directors or Certain Officers
7:40am
8-K
wntohz367556zfz488fg
24 Feb 22
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
6:47am
8-K
0k4zys
7 Feb 22
Departure of Directors or Certain Officers
4:20pm
8-K
2wh9ni99d4 0oji
8 Nov 21
Editas Medicine Announces Third Quarter 2021 Results and Business Updates
7:16am
8-K
5syutat0pwq8
28 Oct 21
Departure of Directors or Certain Officers
9:10am
8-K
5d5iy2v
29 Sep 21
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
9:05am
8-K
lw7cr jmdd4
8 Sep 21
Departure of Directors or Certain Officers
4:21pm
8-K
81z5rso7 y91ms
4 Aug 21
Editas Medicine Announces Second Quarter 2021 Results and Business Updates
7:16am
8-K
s11y8z96tnbvai
8 Jun 21
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
wx79xgr8332u1vx
14 May 21
Entry into a Material Definitive Agreement
4:57pm
8-K
eg92xt40gwjnutvf4
5 May 21
Editas Medicine Announces First Quarter 2021 Results and Update
7:10am
8-K
w4v7wyvoulrdia1n98
25 Feb 21
Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update
7:53am
8-K/A
mm50wak5
19 Feb 21
Departure of Directors or Certain Officers
4:15pm
8-K
yhqie8i4p7w7 ae39b
8 Feb 21
Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer
8:10am
8-K
rkbxu5hlfeeugpl30
21 Jan 21
Editas Medicine Announces Pricing of Offering of Common Stock
4:47pm
8-K
8mhyrv7qbrg4b
19 Jan 21
Results of Operations and Financial Condition
4:37pm
8-K
fijqmquisl awy7hy
11 Jan 21
Departure of Directors or Certain Officers
4:06pm